There’s no notification yet!
Purpose: To determine whether dronabinol administered alone or with megestrol acetate was more, less, or equal in efficacy to single-agent megestrol acetate for palliating cancer-associated anorexia.
Context: The use of the cannabis plant (Cannabis sativa L.) for the palliative treatment of cancer patients has been legalized in multiple jurisdictions including Israel. Yet, not much is currently known regarding the efficacy and patterns of use of cannabis in this setting.
Background and Aims: Inflammatory bowel disease (IBD) patients suffer from significant morbidity and diminished life quality. The plant cannabis is beneficial in various gastrointestinal diseases, stimulating appetite and causing weight gain.
Background: A pilot study (NCT00316563) to determine if delta-9-tetrahydrocannabinol (THC) can improve taste and smell (chemosensory) perception as well as appetite, caloric intake, and quality of life (QOL) for cancer patients with chemosensory alterations.
Purpose: To compare the effects of cannabis extract (CE), delta-9-tetrahydrocannabinol (THC), and placebo (PL) on appetite and quality of life (QOL) in patients with cancer-related anorexia-cachexia syndrome (CACS).
Anorexia is a common symptom in cancer and is associated with increased morbidity and mortality. Yet the pathophysiology is not clearly understood and treatment options are limited. The historical anecdotal benefits of smoking marijuana on nausea, pain, and anorexia led to studies with marijuana and synthetic cannabinoids.1, 2 Delta-9-tetrahydrocannabinol is the principal active agent in marijuana.
The effects of dronabinol on appetite and weight were evaluated in 139 patients with AIDS-related anorexia and ≥2.3 kg weight loss in a multi-institutional study. Patients were randomized to receive 2.5 mg dronabinol twice daily or placebo. Patients rated appetite, mood, and nausea by using a 100-mm visual analogue scale 3 days weekly.
